Nanofiber Drug Revolutionizes Glioblastoma Treatment

Science and medical outlets highlighted promising research by the University of Cincinnati and Johns Hopkins Medicine featuring a nanofiber mesh researchers developed to administer a multidrug treatment for brain cancer.

UC College of Engineering and Applied Science Assistant Professor Daewoo Han and UC Distinguished Research Professor Andrew Steckl, an Ohio Eminent Scholar, embedded three drugs into a coaxial electrospun fiber that created a synergistic effect that showed promise in experiments.

The drugs proved more effective in combination than when administered alone and can provide both immediate and long-lasting doses to kill cancer cells.

Glioblastoma is the most common and aggressive form of brain cancer in adults. Researchers at UC and Johns Hopkins found that the three federally approved drugs used to treat glioblastoma (temozolomide, acriflavine and PT2385) work better in combination than they would alone, a pharmaceutical phenomenon called synergism.

The study on synergistic glioblastoma treatment was published in the journal ACS Biomaterials Science & Engineering. The research was supported with a grant from the National Institutes of Health.

Featured image at top: UC Assistant Professor Daewoo Han holds up nanofiber mesh used to administer a multidrug to treat brain cancer. Photo/Joseph Fuqua II/UC

Ohio Eminent Scholar Andrew Steckl and Daewoo Han have a new study to develop a home test for gingivitis that looks like a covid test strip.

UC Assistant Professor Daewoo Han, left, and Distinguished Research Professor Andrew Steckl collaborated with Johns Hopkins Medicine to develop a treatment for glioblastoma that showed promise in animal trials. Photo/Andrew Higley/UC

/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.